Motif Bio announces intention to float on AIM
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
List view / Grid view
News
First patient enrolled in the New Drugs 4 Bad Bugs (ND4BB) programme
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
Treatment of the first HIV positive patient in ABIVAX’s Phase IIa clinical trial with ABX464
2 February 2015 | By ABIVAX
ABIVAX today announced that enrollment has been initiated and the first HIV positive patient dosed in a Phase IIa clinical trial of ABX464...
CARDIS project to target early-stage cardio vascular disease
2 February 2015 | By Imec
The CARDIS project will develop and validate an early-stage cardio vascular disease detection platform using integrated silicon photonics...
TxCell announces its financial calendar for 2015
30 January 2015 | By TxCell
TxCell SA announces its financial calendar for 2015...
Minister announces £14m investment in stratified medicine
29 January 2015 | By Medical Research Council
Minister for Life Sciences George Freeman announced a further £13.7 million investment in stratified medicine collaborations funded by the Medical Research Council (MRC)...
TxCell receives EUR 1 million milestone payment regarding Ovasave(R) collaboration agreement from Trizell
29 January 2015 | By TxCell
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease...
Tau-based vaccines could transform early Alzheimer’s Disease treatment, says GlobalData Analyst
28 January 2015 | By GlobalData
While current treatments for Alzheimer’s Disease are only able to ease symptoms temporarily, tau-based vaccines may offer a new and more effective way to treat AD in the early course of the disease, says an analyst with research and consulting firm GlobalData...
Genticel business update – fourth quarter 2014
28 January 2015 | By Genticel
Genticel, a French biotechnology company and leading developer of therapeutic vaccines, announces its cash ans cash equivalents and liquid investments position and its highlights from the fourth quarter of 2014...
TxCell receives EUR 1.7 million from Bpifrance for Ovasave(R) clinical development in refractory Crohn’s disease
27 January 2015 | By TxCell
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces the receipt of EUR 1.7 million from Bpifrance...
Genticel to continue per protocol its Phase 2 clinical study with ProCervix after 2nd review by the DSMB
27 January 2015 | By Andrew Lloyd & Associates
The Data and Safety Monitoring Board (DSMB) identified no safety concerns that would require making changes to the conduct of the study...
Syncona LLP and UCL Business PLC announce the formation of Autolus Limited, a cancer immunotherapy company
22 January 2015 | By UCL
Syncona LLP and UCL Business PLC, the wholly-owned technology transfer company of University College London, announce the creation of Autolus Limited...
New Oncology and University Hospital Oslo announce genomic profiling collaboration
22 January 2015 | By B3C newswire
New Oncology and the University Hospital Oslo announced today that they have entered into a collaboration to identify alterations in cancer-related tumour genes that predict a patient’s response or resistance to targeted therapies...
Treeway announces License and Collaboration Agreement with uniQure to develop a Gene Therapy for Amyotrophic Lateral Sclerosis
16 January 2015 | By Treeway B.V.
Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS...
Catalent & Sanofi to collaborate on SMARTag™ antibody-drug conjugate technology with Sanofi’s proprietary antibodies
16 January 2015 | By Catalent
Catalent Pharma Solutions has entered into a collaboration with Sanofi-Aventis Recherche & Développement, a Sanofi Company to implement Catalent’s proprietary SMARTag™ technology in the development of next generation Antibody-Drug Conjugates...
